Fangsheng Pharmaceutical announced that the exclusive product of Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary, was included in the “2025 Medical Insurance Catalogue” for the first time through negotiations, and there were no withdrawals or increases in other major products. This drug is a Class 1.1 innovative traditional Chinese medicine approved for marketing on June 9, 2025. It has not yet been officially marketed for sale. The payment standard is 7 yuan/bag, and it is valid until December 31, 2027. Inclusion in the health insurance catalogue is expected to have a positive impact on the company's future performance and market share, but it will not have a significant impact in the short term.

Fangsheng Pharmaceutical announced that the exclusive product of Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary, was included in the “2025 Medical Insurance Catalogue” for the first time through negotiations, and there were no withdrawals or increases in other major products. This drug is a Class 1.1 innovative traditional Chinese medicine approved for marketing on June 9, 2025. It has not yet been officially marketed for sale. The payment standard is 7 yuan/bag, and it is valid until December 31, 2027. Inclusion in the health insurance catalogue is expected to have a positive impact on the company's future performance and market share, but it will not have a significant impact in the short term.